<DOC>
	<DOCNO>NCT01626222</DOCNO>
	<brief_summary>The present multi-center , open-label , single-arm study aim evaluate efficacy safety , quality life health resource utilization postmenopausal woman hormone receptor positive breast cancer progress follow prior therapy non-steroidal aromatase inhibitor ( NSAI ) treat combination Everolimus Exemestane .</brief_summary>
	<brief_title>4EVER - Efficacy , Safety , Health Economics , Translational Research Postmenopausal Women With Estrogen Receptor Positive Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>In light need new treatment option postmenopausal , hormone receptor positive , HER2 negative woman failure prior non-steroidal aromatase inhibitor ( NSAI ) therapy , BOLERO-2 trial perform demonstrated significant efficacy combinatorial treatment Everolimus Exemestane compare Exemestane monotherapy set . In randomized , double blind , placebo-controlled trial statistically significant improvement progression-free survival ( PFS ) add Everolimus exemestane versus Exemestane alone report . Adding Everolimus determine 2.4-fold prolongation PFS 3.2 7.4 month lower risk cancer progression 56 % woman . These finding confirm independent assessment ( 4.1 vs. 11.0 month , risk reduction : 64 % ) . The quality life data show positive trend Everolimus plus Exemestane treatment arm . ( Baselga 2011 , Hortobagyi 2011 ) . Thus , benefit combinatorial treatment versus Exemestane monotherapy show defined patient population control condition . The primary objective trial ass Overall Response Rate ( ORR ) postmenopausal woman hormone receptor positive breast cancer progress follow prior therapy NSAIs treat combination Everolimus Exemestane . The secondary objective include , Progression free survival ( PFS ) , Overall survival ( OS ) , Safety , Change Quality life score time , Health resource utilization . The exploratory objective reflect scientific interest within treatment metastatic breast cancer modify , applicable , accord current scientific state art time actual analysis . These include : influence age , performance status , cancer activity inflammation anxiety depression ; change serum bone-turnover biomarkers ; Pharmacogenetics Everolimus patient advance breast cancer ; presence molecular characteristic Circulating Tumor Cells ; correlation response Exemestane/Everolimus Proteomic analysis . The present national , multi-center , open-label , single-arm study aim evaluate efficacy safety , quality life health resource utilization combination Everolimus Exemestane broader patient population compare BOLERO-2 , i.e . without limitation number previous chemotherapy line , time point progression NSAI therapy , previous endocrine therapy patient Exemestane monotherapy may enrol . Since combination show significantly improve PFS previous BOLERO-2 trial , ethical reason endocrine comparator drug investigate present study , due low efficacy Exemestane monotherapy ( PFS 3.2 month ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Main Inclusion criterion : Metastatic locally advance breast cancer amenable curative treatment surgery radiotherapy nonsystemic treatment . Histological cytological confirmation estrogen receptor positive ( ER+ ) and/or progesterone receptor positive ( PgR+ ) , human epidermal growth factor receptor 2 ( HER2 ) negative breast cancer Postmenopausal woman . Disease progression follow prior therapy non steroidal aromatase inhibitor ( NSAI ) , define : Recurrence , follow completion adjuvant treatment Letrozole Anastrozole , Progression follow completion Letrozole Anastrozole treatment ABC/MBC . Radiological evidence recurrence progression last systemic therapy prior enrollment . Patients must least one lesion accurately measure bone lesion : lytic mixed ( lytic + sclerotic ) absence measurable disease . Written inform consent obtain screening procedure accord local guideline . Other protocol define inclusion criterion apply . Main Exclusion criterion : HER2overexpressing patient local laboratory testing ( IHC 3+ stain situ hybridization positive ) . Patients nonmeasurable lesion bone metastasis ( e.g . pleural effusion , ascites etc. ) . Previous treatment mTOR inhibitor know hypersensitivity mTOR inhibitor . Symptomatic brain CNS metastasis . Previously treat brain metastasis allow provided patient free symptom , prior radiotherapy brain metastasis four week enrollment dose corticosteroid low ( i.e . â‰¤ 10 mg/d Prednisolone equivalent ) stable least two week prior enrollment . Patients Hepatitis B C history Hepatitis B C. Patients unwilling unable comply protocol . Other protocol define exclusion criterion apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Postmenopausal</keyword>
	<keyword>Estrogen Receptor Positive</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>Locally Advanced</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Everolimus ( RAD001 )</keyword>
	<keyword>Exemestane</keyword>
</DOC>